1-3 of 3
Joachim Baech
Close
Sort by
Journal Articles

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma

Diego Villa, Aixiang Jiang, Carlo Visco, Nicola Crosbie, Rory McCulloch, Michael J. Buege, Anita Kumar, David A. Bond, Jonas Paludo, Matthew J. Maurer, Gita Thanarajasingam, Katharine L. Lewis, Chan Y. Cheah, Joachim Baech, Tarec C. El-Galaly, Laveniya Kugathasan, David W. Scott, Alina S. Gerrie, David Lewis
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4576–4585.
https://doi.org/10.1182/bloodadvances.2023009804
Published: 2023
Includes: Supplemental data
Journal Articles

Risk of diabetes and the impact on preexisting diabetes in patients with lymphoma treated with steroid-containing immunochemotherapy

Joachim Baech, Marianne Tang Severinsen, Andreas K. Øvlisen, Henrik Frederiksen, Peter Vestergaard, Christian Torp-Pedersen, Judit Jørgensen, Michael Roost Clausen, Christian B. Poulsen, Peter Brown, Anne Ortved Gang, Robert Schou Pedersen, Karin Ekström Smedby, Sandra Eloranta, Lasse Hjort Jakobsen, Tarec Christoffer El-Galaly
Journal: Blood Advances
Blood Adv (2022) 6 (15): 4427–4435.
https://doi.org/10.1182/bloodadvances.2021006859
Published: 2022
Includes: Supplemental data
Journal Articles

A randomized trial of alendronate as prophylaxis against loss in bone mineral density following lymphoma treatment

Clinical Trials & Observations
Paw Jensen, Lasse Hjort Jakobsen, Martin Bøgsted, Joachim Baech, Simon Lykkeboe, Marianne Tang Severinsen, Peter Vestergaard, Tarec Christoffer El-Galaly
Journal: Blood Advances
Blood Adv (2022) 6 (8): 2549–2556.
https://doi.org/10.1182/bloodadvances.2021006330
Published: 2022
Includes: Supplemental data